The Opticeutical Standard: Six Pillars, Published in Full

Atumnus Life Sciences today publishes the full text of the Opticeutical Standard — the qualification framework that governs which products may bear the Opticeutical designation. The standard is organised into six pillars. A product qualifies if and only if it meets all six. Partial qualification does not exist.

The published standard is consequential because the category it defines cannot exist without it. The word nutraceutical, in its current usage, has become a synonym for any dietary supplement. The Opticeutical designation is meaningful only insofar as the qualification criteria are strict, public, and verifiable. The publication of the standard is therefore the act that brings the category into operational existence.

The six pillars

• Composition rigor — every active ingredient present in the form, dose, and ratio that the published evidence base supports. No proprietary blends concealing under-dosing.
• Bioavailability — formulation chosen to ensure that the active compound reaches the tissue compartment where it is intended to act, not merely the digestive tract where the pill is broken down.
• Mechanism rationale — every claim made on the label tied to a specific, documented mechanism supported by published research. No claims unmoored from biology.
• Third-party verification — every batch verified by an accredited independent laboratory under USP, NSF, ConsumerLab, or equivalent ISO 17025 accreditation. Identity, potency, and contaminant load on every production run.
• Manufacturing discipline — production at a facility operating under current Good Manufacturing Practice (cGMP) per 21 CFR Part 111, with documented quality systems and chain-of-custody traceability.
• Sourcing integrity — raw materials traced to source, supplier qualified, and substitutions disclosed when they occur. No anonymous sourcing.

What each pillar is designed to exclude

Each pillar exists to exclude a specific category of failure that the dietary supplement industry has tolerated for too long. Composition rigor excludes products that list an ingredient at a level too low to produce the documented effect, hidden behind a proprietary-blend designation. Bioavailability excludes products whose formulation guarantees that the active never reaches its target tissue regardless of dose. Mechanism rationale excludes products whose marketing claims have no foundation in the biology of the active ingredient. Third-party verification excludes products whose label claims are unaudited assertions. Manufacturing discipline excludes products produced in facilities that cannot demonstrate quality control. Sourcing integrity excludes products whose ingredient origin is untraceable.

Together, the six pillars define a tier of dietary supplement that is meaningfully different from the bulk of what the market currently offers. The difference is not exotic. The difference is discipline applied uniformly.

“Partial qualification does not exist. A product meets all six pillars or it does not bear the Opticeutical designation. Selectivity is the point.”

How qualification works

Qualification is granted by Atumnus Life Sciences on a per-product, per-batch basis. Manufacturers and brand owners submit products for review against the six pillars. The submission package includes formulation documentation, sourcing documentation, manufacturing facility credentials, third-party verification protocols, and the published basis for each label claim. Atumnus reviews. Where the submission meets all six pillars, the product is granted the right to bear the Opticeutical designation on its packaging and in its marketing, subject to ongoing batch verification.

Qualification is not granted in perpetuity. It is granted per batch and reviewed against quarterly verification reports. A product that drifts out of qualification — a sourcing change, a manufacturing facility transition, a formulation revision that breaks the bioavailability assumption — loses the designation until the deviation is documented and resolved.

Why peptide-class compounds especially require this discipline

The category was developed in part because the peptide-class bioregulator compounds that are now becoming consumer-available cannot be reliably delivered without all six pillars in place at once. Short-chain peptides are moisture-sensitive, pH-sensitive, and subject to enzymatic degradation. Sourcing variation produces meaningful biological variation in the finished product. Manufacturing discipline that is adequate for a multivitamin is inadequate for a peptide-class formulation. Therapeutic salt carriers, such as the Opti-Salt™ family, address some of the formulation challenges. The standard addresses the rest.

The same discipline applies to any product, peptide-class or otherwise, that wishes to bear the Opticeutical designation. The pillars do not vary by ingredient class. They are applied uniformly. A botanical extract that meets all six qualifies. A peptide-class compound that fails any one does not.

Standard revision and governance

The standard will be revised on a quarterly cadence. Revisions will be published in this newsroom and at the standard reference. Substantive revisions — additions or removals of pillars, material changes to qualification criteria, changes to verification requirements — will be announced thirty days in advance to qualified manufacturers and partners to allow operational adjustment.

Comments, challenges, and revision proposals from qualified manufacturers, independent scientific reviewers, and recognised verification bodies are welcome through the standard governance channel. The standard is published in order to be improved over time. The intention is not finality. The intention is rigour, sustained.